{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-022194","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.440514+00:00","generated_at":"2026-06-15T01:22:38.737407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Erasca Q1 2023 net loss $33.2M; cash $390M; pipeline advances with Phase 3 trial plan","bullets":["Net loss $33.2M ($0.22/share) vs $36.5M ($0.31/share) year ago; R&D $27.6M, G&A $9.4M.","Cash, equivalents & marketable securities $389.7M at March 31, 2023, expected to fund into H2 2025.","Pivotal Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma expected to initiate in H1 2024.","FDA Fast Track Designation granted for ERAS-801 in glioblastoma; Phase 1 data expected H2 2023.","Promoted Shannon Morris to CMO and Chandra Lovejoy to Chief Regulatory Affairs Officer in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-022194","json":"https://secwatch.observer/filing/0000950170-23-022194.json","markdown":"https://secwatch.observer/filing/0000950170-23-022194.md","text":"https://secwatch.observer/filing/0000950170-23-022194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/0000950170-23-022194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/eras-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:22:38.737407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e595b50bec783fa01484de2d4c56fa165841a86","claim":"Erasca, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Erasca, Inc. announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023022194/0000950170-23-022194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}